Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to 30.17%.

  • Cytosorbents' EBITDA Margin rose 259000.0% to 30.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 38.11%, marking a year-over-year increase of 258700.0%. This contributed to the annual value of 47.16% for FY2024, which is 556200.0% up from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' EBITDA Margin is 30.17%, which was up 259000.0% from 37.59% recorded in Q2 2025.
  • Cytosorbents' EBITDA Margin's 5-year high stood at 26.91% during Q1 2021, with a 5-year trough of 111.17% in Q3 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 56.08% (2024), whereas its average is 64.48%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -666500bps in 2021, then soared by 677900bps in 2024.
  • Cytosorbents' EBITDA Margin (Quarter) stood at 88.68% in 2021, then rose by 24bps to 67.69% in 2022, then tumbled by -60bps to 108.54% in 2023, then soared by 62bps to 40.75% in 2024, then grew by 26bps to 30.17% in 2025.
  • Its last three reported values are 30.17% in Q3 2025, 37.59% for Q2 2025, and 44.54% during Q1 2025.